Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS To Increase Flu Vaccine Administration Fees In Final Part B Rule

This article was originally published in The Pink Sheet Daily

Executive Summary

The Center for Medicare & Medicaid Services' final 2005 Physician Fee Schedule is understood to include a payment increase for administration of the flu vaccine to Medicare beneficiaries

You may also be interested in...



Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension

The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.

Reimbursement For ESRD Drugs To Be Based On Average Acquisition Cost

The Centers for Medicare & Medicaid Services will base reimbursement for end-stage renal disease therapies in 2005 on the average acquisition cost

Reimbursement For ESRD Drugs To Be Based On Average Acquisition Cost

The Centers for Medicare & Medicaid Services will base reimbursement for end-stage renal disease therapies in 2005 on the average acquisition cost

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel